Martin Murphy

Martin Murphy

Chief Executive Officer

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust.

Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Autolus, Quell and Anaveon and is a Director of Resolution. He was previously Chairman of Blue Earth Diagnostics, which Syncona sold to Bracco Imaging for $476 million in 2019.

Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

Syncona portfolio companies

  • Anaveon (Chair)
  • Autolus (Chair)
  • Neogene Therapeutics
  • Achilles Therapeutics
  • Quell Therapeutics (Chair)
  • OMass Therapeutics (Board observer )
  • Resolution Therapeutics (Board member)
Chris Hollowood

Chris Hollowood

Chief Investment Officer
Freddie Dear

Freddie Dear

Partner
Kenneth Galbraith

Kenneth Galbraith

Executive in Residence
Lorenz Mayr

Lorenz Mayr

Entrepreneur in Residence
Elisa Petris

Elisa Petris

Partner
Alice Renard

Alice Renard

Partner